All In Biotech

Drug Trial Radar · NCT03354273

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease

Last checked: Nov 20, 2026Latest source record: Jul 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

730

Actual

Start

Jun 5, 2018

Primary completion

May 5, 2022

Study completion May 5, 2022

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
Pharmaceutical Product Development, (PPD) LLC
First posted
Nov 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.

Conditions

  • Coronary Artery Disease (CAD)

Interventions

  • PET MPIDrug

    Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.

  • SPECT MPIDrug

    SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.

  • Pharmacological stress agentsDrug

    Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary Artery Disease (CAD) as Defined by Cardiac CatheterizationTime frame: Up to 60 days

Locations

53 sites in 7 countries. Site status is shown where the registry gives one.

  • Vascular Biology and Hypertension Program, University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California- Los Angeles

    Los Angeles, California

  • Keck Hospital of USC

    Los Angeles, California

  • VA Greater Los Angeles Health Care System

    Los Angeles, California

  • VA San Diego Health System

    San Diego, California

  • UCSF

    San Francisco, California

  • Tower Saint John's Imaging

    Santa Monica, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Cardiology Physicians PA/Red Clay Research LLC

    Newark, Delaware

  • University of Florida

    Gainesville, Florida

  • Indago Research and Health Center

    Hialeah, Florida

  • Optimus U Corp

    Miami, Florida

  • Infinite Clinical Research

    Miami, Florida

  • Allied Biomedical Research Institute

    Miami, Florida

  • Comprehensive Vascular Care PA

    Miami, Florida

  • Amavita Clinical Research, LLC

    North Miami Beach, Florida

  • Emory University

    Atlanta, Georgia

  • University Of Iowa Hospitals And Clinics

    Iowa City, Iowa

  • Midwest Heart and Vascular Specialists

    Overland Park, Kansas

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri

  • VA St. Louis Health Care System

    St Louis, Missouri

  • St Louis University

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center/New York Presbyterian Hospital - Milstein Hospital Building

    New York, New York

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • OhioHealth Research Institute

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Berks Cardiologists, LTD

    Wyomissing, Pennsylvania

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • VA North Texas Health Care System - NAVREF - PPDS

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • The Methodist Hospital Research Institute

    Houston, Texas

  • Vital Heart & Vein

    Humble, Texas

  • Memorial City and Katy Cardiology Associates

    Katy, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

  • Roanoke Heart Institute

    Roanoke, Virginia

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

  • Montreal Heart Institute

    Montreal, Quebec, Canada

  • Center Hospitalier Universitaire de Sherbrooke CHUS

    Montreal, Quebec, Canada

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.